ArticleArchives of virology2026
Construction of recombinant OPIV3 virus vectoring bivalent Mycoplasma ovipneumoniae adhesins.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mycoplasma ovipneumoniae (MO) and Ovine parainfluenza virus type 3 (OPIV3) are significant pathogens implicated in ovine respiratory diseases, which impose substantial threats to extensive sheep farming. However, no commercial bivalent vaccines targeting both pathogens are currently available. In this study, we constructed a recombinant live-attenuated OPIV3 using Red/ET recombination, inserting MO adhesion protein genes (P60, P113) between the N and P genes of the OPIV3 genome. The recombinant candidate rOPIV3-MO was successfully generated and inhibited growth kinetics similar to those of the parental OPIV3 TJ2022 strain. Immunization trials in sheep indicated that rOPIV3-MO displayed a favorable safety profile. Both rOPIV3-MO and OPIV3 TJ2022 inoculation induced specific and neutralizing antibodies, as well as T-cell receptor (TCR) rearrangements.
Indexed as
Identifiers
41711976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.